Home - Products - Others - Other Targets - (Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)

(Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)

CAS No. 142878-79-3

(Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)( ——— )

Catalog No. M39900 CAS No. 142878-79-3

(Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)
  • Note
    Research use only, not for human use.
  • Brief Description
    (Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)
  • Description
    (Tyr0)-C-Type Natriuretic Peptide (32-53) (human, porcine, rat)
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    142878-79-3
  • Formula Weight
    2360.82
  • Molecular Formula
    C102H166N28O30S3
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • HIV-gp41-Antigenic P...

    HIV-gp41-Antigenic Peptide 5

  • Dexrazoxane

    A derivative of EDTA that chelates iron and reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals.

  • Magrolimab

    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.